Sphere Fluidics announced its rebranding to Sphere Bio. The name change marks a significant milestone in the Company’s development, reflecting its transition from a leading droplet-based microfluidics innovator to an established commercial provider of integrated life sciences tools and solutions. Founded in 2010, the Company has been focused on the development of novel single-cell analysis products and R&D services for a growing portfolio of markets, including biologics discovery, cell therapy and synthetic biology.

Researchers invited to gain early access to next-generation platform to optimize functional single-cell analysis workflows across expanded applications in life science R&DSphere Fluidics, a leading provider of innovative picodroplet-based microfluidics solutions for functional single cell analysis and isolation, has announced the launch of Cyto-Mine® Chroma and the opening of its Early Access Program...

Sphere Fluidics, a leading provider of innovative droplet-based microfluidics solutions for single-cell analysis and isolation, today shared details of Cyto-Mine® Chroma, the second generation of its flagship Cyto-Mine platform. This new platform will offer enhanced capabilities, including multiplexing and greater assay flexibility, to further maximize the efficiency and precision of single-cell functional analysis workflows...